Neuropsychopharmacology Reports最新文献

筛选
英文 中文
Efficacy and safety of lemborexant in subjects with insomnia disorder receiving medications for depression or anxiety symptoms. lemborexant在接受抑郁或焦虑症状药物治疗的失眠患者中的疗效和安全性。
IF 2
Neuropsychopharmacology Reports Pub Date : 2025-03-01 Epub Date: 2024-12-04 DOI: 10.1002/npr2.12509
Andrew Krystal, Pierre Blier, Larry Culpepper, Andrew A Nierenberg, Yoshikazu Takaesu, Naoki Kubota, Margaret Moline, Manoj Malhotra, Kate Pinner, Jane Yardley
{"title":"Efficacy and safety of lemborexant in subjects with insomnia disorder receiving medications for depression or anxiety symptoms.","authors":"Andrew Krystal, Pierre Blier, Larry Culpepper, Andrew A Nierenberg, Yoshikazu Takaesu, Naoki Kubota, Margaret Moline, Manoj Malhotra, Kate Pinner, Jane Yardley","doi":"10.1002/npr2.12509","DOIUrl":"10.1002/npr2.12509","url":null,"abstract":"<p><strong>Aim: </strong>Individuals with insomnia frequently have comorbid depression or anxiety. This study sought to provide a preliminary indication of the effects of lemborexant (LEM) in subjects treated for mild depression/anxiety symptoms.</p><p><strong>Methods: </strong>E2006-G000-303 (NCT02952820; EudraCT 2015-001463-39; SUNRISE-2) was a 12-month, phase 3, randomized, placebo-controlled, double-blind study where subjects with insomnia disorder were randomized (1:1:1) to placebo, LEM 5 mg (LEM5), or LEM 10 mg (LEM10) for 6 months. During the second 6 months (not reported), placebo-treated subjects were re-randomized to LEM5 or LEM10. In this post hoc analysis, changes from baseline (CFB) in subject-reported (subjective) sleep onset latency (sSOL), sleep efficiency (sSE), wake after sleep onset (sWASO), total sleep time (sTST), Fatigue Severity Scale, and Insomnia Severity Index were evaluated in subjects treated with medications for symptoms of depression/anxiety (subpopulation).</p><p><strong>Results: </strong>Of 949 randomized subjects, 61 treated with medications for symptoms of depression/anxiety were included. In the subpopulation, CFB comparing LEM with placebo were generally smaller than the overall population due to a larger placebo response in the subpopulation. However, the magnitudes of CFB within the active treatment groups for sSOL, sWASO, sTST, and sSE were similar between the subpopulation and the overall population. No new safety signals were observed in the subpopulation.</p><p><strong>Conclusion: </strong>LEM treatment benefited subjects with insomnia treated with medications for depression/anxiety symptoms, with no new safety signals. A greater placebo response in the subpopulation than in the overall population decreased the drug versus placebo effect size for LEM, as has been reported for other insomnia medications.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12509"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guideline for pharmacological treatment of schizophrenia 2022. 精神分裂症药物治疗指南 2022。
IF 2
Neuropsychopharmacology Reports Pub Date : 2025-03-01 Epub Date: 2024-11-25 DOI: 10.1002/npr2.12497
{"title":"Guideline for pharmacological treatment of schizophrenia 2022.","authors":"","doi":"10.1002/npr2.12497","DOIUrl":"10.1002/npr2.12497","url":null,"abstract":"","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12497"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666347/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics of psychiatric patients with nightmares after suvorexant administration: A retrospective study. 精神病患者服用过量后噩梦的特征:一项回顾性研究。
IF 2
Neuropsychopharmacology Reports Pub Date : 2025-03-01 Epub Date: 2024-11-29 DOI: 10.1002/npr2.12506
Kazuya Yasuda, Yoji Hirano, Ryuichiro Takeda, Ryuji Ikeda, Yasushi Ishida
{"title":"Characteristics of psychiatric patients with nightmares after suvorexant administration: A retrospective study.","authors":"Kazuya Yasuda, Yoji Hirano, Ryuichiro Takeda, Ryuji Ikeda, Yasushi Ishida","doi":"10.1002/npr2.12506","DOIUrl":"10.1002/npr2.12506","url":null,"abstract":"<p><strong>Aim: </strong>Suvorexant is an orexin receptor antagonist (ORA) for the treatment of insomnia. The antagonistic action of suvorexant on orexin receptors is associated with an increase in rapid eye movement (REM) sleep, which can potentially lead to nightmares depending on the patient's condition. However, the precise risk factors for nightmares among patients taking ORAs, such as suvorexant, have yet to be identified. In this retrospective study, we aimed to identify the risk factors for the development of nightmares in patients treated with suvorexant.</p><p><strong>Methods: </strong>The risk factors were determined by comparing parameters between the nightmare group and the nonnightmare group. This study included 440 patients who received suvorexant at the University of Miyazaki Hospital from April 2014 to January 2021.</p><p><strong>Results: </strong>We found that 9.1% (n = 40) of the patients experienced suvorexant-induced nightmares. There was a significant difference in the median age, which was lower in the nightmare group than in the nonnightmare group (p < 0.01). Furthermore, both multiple logistic regression analysis and Cox proportional hazards regression analysis revealed increased odds ratios for nightmares for individuals aged 20-39 years.</p><p><strong>Conclusions: </strong>This study revealed that elderly patients taking suvorexant had fewer nightmares than nonelderly patients did.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12506"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666341/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Pharmacological Interventions in Milder Depression: A Systematic Review and Meta-Analysis.
IF 2
Neuropsychopharmacology Reports Pub Date : 2025-03-01 DOI: 10.1002/npr2.70008
Minoru Urata, Hitoshi Sakurai, Fumihiko Ueno, Taku Maruki, Teruo Tada, Takahito Uchida, Yasuyuki Matsumoto, Masami Murao, Masayuki Tomita, Hajime Baba, Masaki Kato, Takashi Tsuboi, Koichiro Watanabe
{"title":"Efficacy of Pharmacological Interventions in Milder Depression: A Systematic Review and Meta-Analysis.","authors":"Minoru Urata, Hitoshi Sakurai, Fumihiko Ueno, Taku Maruki, Teruo Tada, Takahito Uchida, Yasuyuki Matsumoto, Masami Murao, Masayuki Tomita, Hajime Baba, Masaki Kato, Takashi Tsuboi, Koichiro Watanabe","doi":"10.1002/npr2.70008","DOIUrl":"10.1002/npr2.70008","url":null,"abstract":"<p><strong>Background: </strong>Mild depression lacks a consistent definition across diagnostic criteria and rating scales, posing challenges to standardizing treatment strategies. International guidelines predominantly recommend psychotherapy as the first-line treatment for mild depression, while the use of antidepressants remains contentious. Supplements such as omega-3 fatty acids, St. John's Wort, and magnesium have garnered attention as alternative therapeutic options for depression. This systematic review aims to assess the efficacy of pharmacological interventions, including supplements, in the treatment of mild depression.</p><p><strong>Methods: </strong>Comprehensive searches were performed in PubMed and Embase through November 2024 to identify randomized controlled trials (RCTs) investigating pharmacotherapy or supplements for mild depression diagnosed using standardized criteria. Eligible studies underwent screening and risk of bias assessment utilizing the ROB2 tool. Data on remission rates, symptom improvement, dropout rates, and adverse events were extracted, with meta-analyses conducted where applicable.</p><p><strong>Results: </strong>Eight RCTs comprising 1049 participants met inclusion criteria. Among the agents studied, St. John's Wort was analyzed in two trials, both comparing it to fluoxetine. A meta-analysis found no significant difference in response rates between the two treatments (risk ratio [RR] = 0.96, 95% CI: 0.78-1.18) or dropout rates (RR = 1.08, 95% CI: 0.62-1.88). For other agents, single studies evaluated their effects. Eicosapentaenoic acid and Rhodiola rosea demonstrated significant improvements in depressive symptoms compared to placebo. In non-blinded trials, magnesium chloride showed efficacy in alleviating depressive symptoms. Other interventions, such as lavender, lemon balm, and transcranial electroacupuncture stimulation, were as effective as antidepressants. Conversely, S-adenosylmethionine did not produce significant improvements relative to placebo.</p><p><strong>Conclusion: </strong>This review demonstrates that certain supplements, such as eicosapentaenoic acids and Rhodiola rosea, are therapeutic options for mild depression. However, no RCTs compared antidepressants directly to placebo for mild depression. The paucity of high-quality RCTs exclusively targeting mild depression limits definitive conclusions, warranting further rigorous research.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"45 1","pages":"e70008"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11867163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fluoxetine does not influence response to continuous theta burst stimulation in human motor cortex. 氟西汀不会影响人类运动皮层对连续θ脉冲刺激的反应。
IF 2
Neuropsychopharmacology Reports Pub Date : 2025-03-01 Epub Date: 2024-11-07 DOI: 10.1002/npr2.12493
Duncan K Austin, Lourenço M D Amador, Lucia M Li, Simon J Little, John C Rothwell
{"title":"Fluoxetine does not influence response to continuous theta burst stimulation in human motor cortex.","authors":"Duncan K Austin, Lourenço M D Amador, Lucia M Li, Simon J Little, John C Rothwell","doi":"10.1002/npr2.12493","DOIUrl":"10.1002/npr2.12493","url":null,"abstract":"<p><strong>Aim: </strong>Selective serotonin reuptake inhibitors are thought to exert a clinical effect through various mechanisms, including through alteration in synaptic plasticity. Repetitive transcranial magnetic stimulation can induce temporary changes in synaptic excitability in cerebral cortex that resemble long-term potentiation and long-term depression that serve as a measure of synaptic plasticity in vivo. A version of repetitive transcranial magnetic stimulation called continuous theta burst stimulation can induce inhibition of cortical excitability that can be measured through a motor evoked potential. Previous work has suggested that this response can be modulated by administration of selective serotonin reuptake inhibitors.</p><p><strong>Method: </strong>Thirty-one healthy volunteers received both fluoxetine 20 mg and placebo in randomly ordered sessions, followed by spaced continuous theta burst stimulation to motor cortex. Changes in Motor Evoked Potentials were then recorded over 60 min.</p><p><strong>Results: </strong>The response to spaced continuous theta burst stimulation did not differ significantly between fluoxetine and placebo sessions. Spaced continuous theta burst stimulation produced a paradoxical excitatory response in an unexpected number of participants.</p><p><strong>Conclusion: </strong>A single dose of fluoxetine 20 mg does not influence the response to continuous theta burst stimulation. Previous results suggesting an effect of selective serotonin reuptake inhibitors on inhibitory non-invasive brain stimulation protocols may be due to insufficiently large sample sizes.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12493"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11660763/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of repetitive transcranial magnetic stimulation therapy on weight and lipid metabolism in patients with treatment-resistant depression: A preliminary single-center retrospective cohort study. 重复经颅磁刺激疗法对耐药抑郁症患者体重和脂质代谢的影响:一项初步的单中心回顾性队列研究。
IF 2
Neuropsychopharmacology Reports Pub Date : 2025-03-01 Epub Date: 2024-11-09 DOI: 10.1002/npr2.12494
Ami Nakazawa, Yuki Matsuda, Ryuichi Yamazaki, Nanase Taruishi, Shinsuke Kito
{"title":"Effects of repetitive transcranial magnetic stimulation therapy on weight and lipid metabolism in patients with treatment-resistant depression: A preliminary single-center retrospective cohort study.","authors":"Ami Nakazawa, Yuki Matsuda, Ryuichi Yamazaki, Nanase Taruishi, Shinsuke Kito","doi":"10.1002/npr2.12494","DOIUrl":"10.1002/npr2.12494","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to elucidate the effects of repetitive transcranial magnetic stimulation (rTMS) on weight, body mass index (BMI), and lipid metabolism in patients with treatment-resistant depression (TRD).</p><p><strong>Methods: </strong>This retrospective observational study included patients with TRD who received rTMS treatment at the Jikei University Hospital from September 2018 to August 2021. The patients were diagnosed based on the DSM-5 and ICD-10 criteria and treated using the NeuroStar TMS System. For 3-6 weeks, 10-Hz rTMS was administered to the left dorsolateral prefrontal cortex at 120% motor threshold. The primary outcomes were changes in weight and BMI, whereas the secondary outcomes included changes in total, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol levels, thyroid function indicators, as well as HAMD-17, HAMD-24, and Montgomery-Åsberg Depression Rating Scale (MADRS) scores. Statistical analysis was conducted using paired t-tests and repeated measures ANOVA.</p><p><strong>Results: </strong>Among the 34 patients (20 men and 14 women) included, no significant changes were observed in weight or BMI after rTMS treatment (average weight reduction: -0.50 kg, 95% CI: -0.14 to 0.56, p = 0.24; average BMI reduction: -0.21, 95% CI: -0.10 to 0.61, p = 0.15). However, significant reductions in total, HDL, and LDL cholesterol levels and FT4 were observed. Furthermore, the HAMD-17, HAMD-24, and MADRS scores significantly increased post-treatment.</p><p><strong>Conclusion: </strong>rTMS treatment did not affect weight or BMI in patients with TRD but is believed to improve lipid metabolism.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12494"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11660761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142624861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dysregulated HPA axis during postnatal developmental stages in the BTBR T+ Itpr3tf/J mouse: A model of autism spectrum disorder. BTBR T+ Itpr3tf/J小鼠出生后发育阶段HPA轴异常:自闭症谱系障碍模型
IF 2
Neuropsychopharmacology Reports Pub Date : 2025-03-01 Epub Date: 2024-11-28 DOI: 10.1002/npr2.12508
Nozomi Endo, Atsuo Hiraishi, Sayaka Goto, Hitoshi Nozu, Takayo Mannari-Sasagawa, Noriko Horii-Hayashi, Michiko Kitsuki, Mamiko Okuda, Manabu Makinodan, Mayumi Nishi
{"title":"Dysregulated HPA axis during postnatal developmental stages in the BTBR T<sup>+</sup> Itpr3<sup>tf</sup>/J mouse: A model of autism spectrum disorder.","authors":"Nozomi Endo, Atsuo Hiraishi, Sayaka Goto, Hitoshi Nozu, Takayo Mannari-Sasagawa, Noriko Horii-Hayashi, Michiko Kitsuki, Mamiko Okuda, Manabu Makinodan, Mayumi Nishi","doi":"10.1002/npr2.12508","DOIUrl":"10.1002/npr2.12508","url":null,"abstract":"<p><p>Autism spectrum disorder (ASD) is a neurodevelopmental disorder. Some children with ASD show enhanced cortisol response to stress. BTBR T<sup>+</sup> Itpr3<sup>tf</sup>/J (BTBR) mice, an ASD model, display behavior consistent with the three diagnostic categories of ASD and exhibit an exaggerated response to stress in adulthood. However, it remains unclear how basal corticosterone levels change and how the hypothalamic-pituitary-adrenal axis responds to stress during the early life stages in BTBR mice. In this study, we found that basal corticosterone levels showed characteristic changes, peaking at weaning during postnatal development in both BTBR and control C57BL/6J (B6J) mice. Furthermore, we observed higher corticosterone and corticotropin-releasing hormone levels in BTBR mice than in B6J mice following acute stress exposure during weaning; however, adrenocorticotropic hormone levels were lower in BTBR mice. Glucocorticoid receptor mRNA expression levels in the hippocampus and lateral septum after stress were higher in BTBR mice than in B6J mice. This study documented changes in corticosterone levels at baseline during postnatal development in mice and showed that BTBR mice exhibited disrupted stress responses at weaning.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12508"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11660766/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142751326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Initial psychotropic prescriptions and symptom associations in first-visit patients with major depressive disorder: A single-center cross-sectional study. 重度抑郁障碍初诊患者的初始精神药物处方和症状关联:单中心横断面研究。
IF 2
Neuropsychopharmacology Reports Pub Date : 2025-03-01 Epub Date: 2024-11-20 DOI: 10.1002/npr2.12507
Yugo Ishihara, Norio Sugawara, Yasushi Kawamata, Norio Yasui-Furukori
{"title":"Initial psychotropic prescriptions and symptom associations in first-visit patients with major depressive disorder: A single-center cross-sectional study.","authors":"Yugo Ishihara, Norio Sugawara, Yasushi Kawamata, Norio Yasui-Furukori","doi":"10.1002/npr2.12507","DOIUrl":"10.1002/npr2.12507","url":null,"abstract":"<p><strong>Aim: </strong>There are limited reports regarding psychotropic prescriptions in first-visit patients with major depressive disorder (MDD). The objective of this study is to clarify the prescription patterns of psychotropics and their association with symptoms among first-visit patients with MDD in Japan.</p><p><strong>Methods: </strong>In this cross-sectional analysis, we examined 376 first-visit patients diagnosed with MDD. Depressive symptoms were evaluated using the Quick Inventory of Depressive Symptomatology Japanese version (QIDS-J). To assess personality traits, we administered the Japanese version of the Ten Item Personality Inventory (TIPI-J), and psychotic symptoms were evaluated using the PRIME Screen-Revised (PS-J).</p><p><strong>Results: </strong>Among the first-visit patients with MDD, 31.4% (118/376) were prescribed antidepressants, and 18.1% (68/376) received benzodiazepines. Overall, 40.2% (151/376) of the patients were prescribed at least one psychotropic medication. In a multivariate logistic regression model using the forced entry method, missing data on educational attainment and the view of myself domain of the QIDS-J were negatively associated, while the concentration/decision-making domain of the QIDS-J was positively associated with antidepressant prescription.</p><p><strong>Conclusion: </strong>More than half of the first-visit patients did not receive any psychotropic medication. Psychiatrists appear to consider specific symptoms and personality traits when deciding whether to prescribe medications, which may also be influenced by patient preferences. Further studies, including longitudinal analyses, are needed to explore these associations in more detail.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12507"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibitory effects of the selective μ-opioid receptor antagonist UD-030 on methamphetamine-induced conditioned place preference. 选择性μ-阿片受体拮抗剂UD-030对甲基苯丙胺诱导的条件性位置偏好的抑制作用
IF 2
Neuropsychopharmacology Reports Pub Date : 2025-03-01 Epub Date: 2024-11-27 DOI: 10.1002/npr2.12503
Soichiro Ide, Noriaki Iwase, Kenichi Arai, Masahiro Kojima, Shigeru Ushiyama, Kazutaka Ikeda
{"title":"Inhibitory effects of the selective μ-opioid receptor antagonist UD-030 on methamphetamine-induced conditioned place preference.","authors":"Soichiro Ide, Noriaki Iwase, Kenichi Arai, Masahiro Kojima, Shigeru Ushiyama, Kazutaka Ikeda","doi":"10.1002/npr2.12503","DOIUrl":"10.1002/npr2.12503","url":null,"abstract":"<p><p>Although methamphetamine (METH) and other addictive substance use disorders are a major social problem worldwide, appropriate pharmacotherapies have not yet been discovered. Subtype-nonselective opioid receptor antagonists, such as naltrexone (NTX), have been reported to suppress METH addiction, but unclear are the opioid receptor subtypes that are involved in this beneficial effect. To clarify the role of μ-opioid receptors (MOPs), we examined effects of the novel nonpeptidic MOP-selective antagonist UD-030 on the acquisition and expression of METH-induced conditioned place preference (CPP) using behavioral tests in C57BL/6J mice. UD-030 was found to inhibit both the acquisition and expression of METH-induced CPP in a dose-dependent manner, with effects comparable to those observed with NTX. These findings suggest that UD-030 has the potential to mitigate METH-related reward mechanisms and may serve as a promising candidate for MOP-selective pharmacotherapy targeting METH addiction.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12503"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142731164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of Anhedonia on the Disease Burden of Major Depressive Disorder in the Asia-Pacific Region: A Cross-Sectional Real-World Study.
IF 2
Neuropsychopharmacology Reports Pub Date : 2025-03-01 DOI: 10.1002/npr2.70007
Keira Herr, Michael Berk, Wei-Lieh Huang, Tadafumi Kato, Jung Goo Lee, Chong Guan Ng, Zhen Wang, Thomas Webb, Mami Kasahara-Kiritani, Lawrence Vandervoort
{"title":"The Impact of Anhedonia on the Disease Burden of Major Depressive Disorder in the Asia-Pacific Region: A Cross-Sectional Real-World Study.","authors":"Keira Herr, Michael Berk, Wei-Lieh Huang, Tadafumi Kato, Jung Goo Lee, Chong Guan Ng, Zhen Wang, Thomas Webb, Mami Kasahara-Kiritani, Lawrence Vandervoort","doi":"10.1002/npr2.70007","DOIUrl":"10.1002/npr2.70007","url":null,"abstract":"<p><strong>Aim: </strong>Anhedonia is a key symptom of major depressive disorder (MDD), however, its burden in patients with MDD is not well understood. We aimed to assess the impact of anhedonia on health-related quality of life (HRQoL), health-care resource utilization (HRU), and work productivity in subjects with MDD and anhedonia (MDD-ANH) compared to subjects with MDD without ANH (MDD non-ANH).</p><p><strong>Methods: </strong>A cross-sectional web-based survey was conducted across six countries/territories. Adult participants were categorized as MDD-ANH, MDD non-ANH, and General Population based on self-reported MDD diagnosis, Patient Health Questionnaire (PHQ-9), and Snaith-Hamilton Pleasure Scale (SHAPS). Multivariate/generalized linear regression modeling (GLMs) and mediation analysis were used to assess anhedonia's impact on HRQoL/function, HRU, and work productivity.</p><p><strong>Results: </strong>Among 11 383 respondents, 20.1% were identified with MDD (MDD-ANH: 12.7%; MDD non-ANH: 7.3%) and 79.9% as General Population. Subjects with MDD-ANH, compared with MDD non-ANH demonstrated significantly worse or lower sexual functioning, HRQoL (RAND mental/physical component summary, health state utility (EuroQol) Index scores, all p < 0.001), and higher HRU (psychiatrist visits). Work productivity (higher absenteeism/overall work productivity or daily life impairment scores; all p < 0.05) was significantly worse in subjects with MDD-ANH compared with MDD non-ANH.</p><p><strong>Conclusion: </strong>Anhedonia in patients with MDD had a significant negative impact on HRQoL, sexual functioning, work productivity, and HRU, emphasizing the need for focus on anhedonia management in MDD patients in the Asia-Pacific region.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"45 1","pages":"e70007"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信